| First Author | Esquivel RN | Year | 2019 |
| Journal | Mol Ther | Volume | 27 |
| Issue | 5 | Pages | 974-985 |
| PubMed ID | 30962164 | Mgi Jnum | J:349642 |
| Mgi Id | MGI:6391616 | Doi | 10.1016/j.ymthe.2019.03.005 |
| Citation | Esquivel RN, et al. (2019) In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus. Mol Ther 27(5):974-985 |
| abstractText | Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs), which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody, supporting the importance of this new platform. |
